Literature DB >> 11472319

Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.

S Sanduleanu1, D Jonkers, A De Bruïne, W Hameeteman, R W Stockbrügger.   

Abstract

BACKGROUND: Long-term acid suppression may accelerate the development of atrophic gastritis in Helicobacter pylori-positive subjects. The pathogenetic mechanism remains unclear. AIM: To test the hypothesis that gastric double infection with H. pylori and non-H. pylori bacterial species-during acid suppression-may result in an enhanced inflammatory response, contributing to the development of atrophic gastritis. PATIENTS AND METHODS: A consecutive series of patients with gastro-oesophageal reflux disease undergoing treatment with proton pump inhibitors (n=113) or histamine2-receptor antagonists (H2-RAs) (n=37), and 76 non-treated dyspeptic controls were investigated. Gastric mucosal H. pylori and non-H. pylori bacteria, histological gastritis, H. pylori serology, and circulating interleukin (IL)-1beta, IL-6, and IL-8 were examined.
RESULTS: Patients on acid suppression with either proton pump inhibitors or H2-RAs had a similar prevalence of H. pylori infection to the controls, but a higher prevalence of non-H. pylori bacteria (61% and 60% vs. 29%, P < 0.0001 and P < 0.002). Both the presence of H. pylori and non-H. pylori bacteria were independent risk factors of atrophic gastritis (antrum: relative risks (RRs), 10.1 and 5.07; corpus: RRs, 11.74 and 6.38). A simultaneous presence of H. pylori and non-H. pylori bacteria was associated with a markedly increased risk of atrophic gastritis (antrum: RR, 20.25; corpus: RR, 20.38), compatible with a synergistic effect. Furthermore, the simultaneous presence of both types of bacteria was associated with higher cytokine levels than in patients without any type of bacteria. This increase was also greater than in patients with H. pylori infection alone (P < 0.001, for both IL-1beta and IL-8). SUMMARY AND
CONCLUSIONS: H. pylori-positive patients on long-term acid inhibition displayed three features: non-H. pylori bacterial growth; increased cytokine levels; and a higher risk of atrophic gastritis. We suggest that double infection with H. pylori and non-H. pylori bacteria is a major factor in the development of atrophic gastritis during gastric acid inhibition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472319     DOI: 10.1046/j.1365-2036.2001.01029.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Proton pump inhibitors and gastric neoplasia.

Authors:  E J Kuipers
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 2.  Proton-pump inhibitors: understanding the complications and risks.

Authors:  Peter Malfertheiner; Arne Kandulski; Marino Venerito
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 3.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

4.  Analysis of culturable microbiota present in the stomach of children with gastric symptoms.

Authors:  Changcheng Guo; Fang Liu; Li Zhu; Fangcao Wu; Guzhen Cui; Yan Xiong; Qiong Wang; Lin Yin; Caixia Wang; Huan Wang; Xiaojuan Wu; Zhengrong Zhang; Zhenghong Chen
Journal:  Braz J Microbiol       Date:  2018-12-19       Impact factor: 2.476

5.  Bacterial flora concurrent with Helicobacter pylori in the stomach of patients with upper gastrointestinal diseases.

Authors:  Yuan Hu; Li-Hua He; Di Xiao; Guo-Dong Liu; Yi-Xin Gu; Xiao-Xia Tao; Jian-Zhong Zhang
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

Review 6.  Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer.

Authors:  Hideyuki Ubukata; Hiroyuki Nagata; Takanobu Tabuchi; Satoru Konishi; Teruhiko Kasuga; Takafumi Tabuchi
Journal:  Gastric Cancer       Date:  2011-01-20       Impact factor: 7.370

Review 7.  Upper gastrointestinal microbiota and digestive diseases.

Authors:  Zi-Kai Wang; Yun-Sheng Yang
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

Review 8.  Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism.

Authors:  Francesco Russo; Michele Linsalata; Antonella Orlando
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

9.  Evaluation of Lineage Changes in the Gastric Mucosa Following Infection With Helicobacter pylori and Specified Intestinal Flora in INS-GAS Mice.

Authors:  Carolina Pinzon-Guzman; Anne R Meyer; Rachel Wise; Eunyoung Choi; Sureshkumar Muthupalani; Timothy C Wang; James G Fox; James R Goldenring
Journal:  J Histochem Cytochem       Date:  2018-07-03       Impact factor: 2.479

10.  Comparison of Gastric Microbiota Between Gastric Juice and Mucosa by Next Generation Sequencing Method.

Authors:  Jihee Sung; Nayoung Kim; Jaeyeon Kim; Hyun Jin Jo; Ji Hyun Park; Ryoung Hee Nam; Yeong-Jae Seok; Yeon-Ran Kim; Dong Ho Lee; Hyun Chae Jung
Journal:  J Cancer Prev       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.